New drug cocktail shows promise for incurable liver cancer
NCT ID NCT05320692
First seen Jan 05, 2026 · Last updated Apr 29, 2026 · Updated 17 times
Summary
This study tests whether adding two drugs (camrelizumab and rivoceranib) to a standard liver cancer procedure (TACE) helps people with incurable liver cancer live longer without their cancer growing. About 423 adults with liver cancer that cannot be removed by surgery are taking part. The main goal is to see if the combination delays cancer progression compared to TACE alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.